The Managed Care Review Board™ ─ Recommendations for the Improved Management of COPD Web Activity

• Release date: March 11, 2016
• Expiration date: September 30, 2017
• Estimated Time to Complete Activity: 1.25 hours
• Compatible with all modern browsers and mobile devices

Distinguished Faculty Presenters

Carl Asche, PhD, MBA, MSc Director Center for Outcomes Research University of Illinois College of Medicine at Peoria Click here for biography Angela Golden, DNP, FNP-C, FAANP Family Nurse Practitioner NP from Home, LLC Family Nurse Practitioner North Country Community Health Center Click here for biography Nicola Hanania, MD, MS Associate Professor Department of Pulmonary and Critical Care Baylor College of Medicine Click here for biography Kenneth Schaecher, MD, FACP, CPC Medical Director SelectHealth Click here for biography

Target Audience

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for chronic obstructive pulmonary disease (COPD) including: physicians, pharmacists, registered nurses, and case managers

Statement of Need 
Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable disease which affects more than fifteen million Americans, with more than 50% of adults with low pulmonary function unaware that they have COPD. It is the third leading cause of death in the United States, responsible for greater than 130,000 deaths each year. Currently diagnosis, assessment, and therapeutic management are based almost exclusively on the severity of airflow limitation; however, each patient’s comorbidities differ and many cannot be successfully managed with just a single intervention necessitating an overall care approach in order to improve treatment outcomes. As the COPD treatment landscape evolves, treatment management decision-making is becoming more complex and MCOs and other payer organizations need to appropriately and effectively design benefit that optimize both cost-efficiency and patient outcomes. This activity is aimed at improving the understanding among managed care providers of the need to establish correct diagnosis, initiate appropriate therapeutic intervention(s), recognize and treat common comorbidities, coordinate activates of a multidisciplinary COPD care team, recognize and treat exacerbations, and provide effective patient education.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Discuss COPD guidelines and the evolving treatment landscape of COPD
• Explain the importance of early recognition of patients at risk, accurate diagnosis of COPD, utilizing spirometry, and understanding the benefits of both non-pharmacologic disease management and pharmacologic treatment
• Illustrate the need to diagnose and manage comorbid conditions in COPD patients
• Employ strategies to increase coordination of care for patients with COPD among multidisciplinary care teams within the managed care setting to optimize transition of care
• Examine differences between asthma and COPD exacerbation and review COPD exacerbation management strategies
• Apply practical strategies to increase health plan members’ knowledge of the disease and its management
• Provide accurate and appropriate counsel as part of the managed care treatment team
• Provide appropriate care and counsel for patients and their families

ACCREDITATION

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

	Accreditation Statement  Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number – 0809-9999-16-143-H01-P

Type of Activity
Knowledge

Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

Nursing Continuing Education

Credit Designation
This educational activity for 1.2 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period March 11, 2016 through September 30, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.